The SAVER™: a Novel CPR Adjunct
The Problem
There are over 650,000 cardiac arrest cases per year in the United States, 90% of which end in fatalities. Of the surviving population, only 9% of them survive without neurologic impairment. CPR is a technique that has not changed much since its inception in the 1960s, and while education initiatives and technological advances (e.g. the AED) have occurred in this space, there has been little change to the standard of care.
How might we improve CPR outcomes through the development of a non-invasive, user-friendly CPR adjunct device to be deployed during CPR?
Our Solution
The SAVER™ is a novel, patent-pending CPR adjunct device that aims to improve CPR outcomes through preferentially redirecting blood perfusion to key areas of the body. Preferentially perfusing key organs such as the heart and brain will increase chances of survival and reduce the potential for neurologic impairment. The SAVER™ is easy-to-use and can be applied to the patient without interrupting current standard of care. The device can be deployed both in the field and in hospital settings, and will ultimately be found wherever an AED is stored.
Research Strategy
The SAVER™ Team is currently engaged in iterative product development at the Medical University of South Carolina. A pilot study in pig models as well as a clinical trial on healthy human controls have also been conducted to validate our proof-of-concept. Next steps include pursuing a larger research study about the SAVER™’s viability, usability, and feasibility.
How to Get Involved
Our team is growing rapidly and
always looking for new talent, expertise, and collaborators. For more information about how to get involved, please contact us to get plugged in.
The SAVER™ Milestones
November 2020: The SAVER™ takes 1st place in the South Carolina Innovates Competition
December 2020: Heartbeat Technologies LLC formed
February 2021: US provisional patent application filed and accepted for The SAVER technology
March 2021: High Innovation High Reward grant awarded, MUSC Student Innovation Week Winner
August 2021: VentureWell Phase I, XLerate Health Accelerator Program
January 2022: VentureWell Phase II
February 2022: Southeastern Surgical Congress Shark Tank 1st Place, VentureWell Innovator Award, utility patent filed, proof-of-concept clinical trial beings at MUSC
March 2022: SAGES Shark Tank Finalist
May 2022: AdvanSE Life Sciences Conference Pitch
June 2022: Cardiac arrest animal study begins
July 2022: Heartbeat Technologies named as 2022 InnoVision Awards finalist
August 2022: Heartbeat Technologies featured in General Surgery News